Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel S Chen

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Plos One|September 15, 2010
Molecular biomarker analyses using circulating tumor cellsElizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerAdrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyF Stephen Hodi, Marcus Ballinger, Benjamin Lyons, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.
Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.
Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Plos One|September 15, 2010
Molecular biomarker analyses using circulating tumor cellsElizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerAdrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyF Stephen Hodi, Marcus Ballinger, Benjamin Lyons, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.
Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.
Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Pageof 4